| 词条 | Tislelizumab |
| 释义 |
| type = mab | image = | alt = | mab_type = mab | source = zu | target = PD-1 | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_AU_comment = | legal_CA = | legal_UK = | legal_US = | legal_UN = | legal_NZ = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action= | excretion = | CAS_number = | ATC_prefix = none | ATC_suffix = | PubChem = | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 0KVO411B3N | DrugBank = | KEGG = D11487 | ChemSpiderID = none | synonyms = BGB-A317 }}Tislelizumab[1][2] (BGB-A317) is a humanized monoclonal antibody directed against PD-1.[3] It prevents PD-1 from binding to the ligands PD-L1 and PD-L2 (hence it is a checkpoint inhibitor). It is being investigated as a treatment for advanced solid tumors.[3] It is designed to bind less to Fc gamma receptors.[5] It is being developed by BeiGene and Celgene Corp.[6] Clinical trialsPhase I trials began in the US and Australia in June 2015 and were expected to complete in mid-2017.[4] Some early results were announced in July 2016.[5][3] A pivotal phase 2 clinical trial for urothelial cancer started in China in 2017.[6] It is in a phase 3 trial for NSCLC.[7] A multicenter phase 3 trial for advanced hepatocellular carcinoma started in Jan 2018.[8] PharmacokineticsEarly phase I clinical trial results give an elimination half-life of 11 to 17 days.[3] References1. ^BGB-A317 {{monoclonals for immune system}}2. ^BeiGene Presents Initial Phase 1b Data for BTK Inhibitor Zanubrutinib (BGB-3111) Combined with PD-1 Antibody Tislelizumab (BGB-A317) ... Dec 2017 3. ^1 2 3 A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors. ASCO 2016 4. ^[https://clinicaltrials.gov/show/NCT02407990 Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors] 5. ^[https://immuno-oncologynews.com/2016/07/26/beigene-presents-initial-clinical-data-showing-anti-cancer-activity-in-range-of-solid-tumors/ Early Results of Immunotherapy Study Showing Anti-Cancer Activity in Range of Solid Tumors July 2016] 6. ^1 [https://www.streetinsider.com/Corporate+News/BeiGene+%28BGNE%29+Commences+Pivotal+Trial+of+PD-1+Antibody+BGB-A317+in+China+in+Patients+with+Urothelial+Cancer/13068864.html BeiGene (BGNE) Commences Pivotal Trial of PD-1 Antibody BGB-A317 in China in Patients with Urothelial Cancer. July 2017] 7. ^[https://clinicaltrials.gov/ct2/show/NCT03358875 Comparison of Efficacy and Safety of Anti-PD-1 Antibody BGB-A317 Versus Docetaxel as Treatment in the Second- or Third-line Setting in Patients With NSCLC] 8. ^1 [https://globenewswire.com/news-release/2018/01/02/1276905/0/en/BeiGene-Initiates-Global-Phase-3-Trial-of-Anti-PD-1-Antibody-Tislelizumab-in-Patients-with-Hepatocellular-Carcinoma.html BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Hepatocellular Carcinoma Jan 2018] 2 : Monoclonal antibodies|Experimental drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。